Generalized Anxiety DisorderNCT04512378
Group CBT for Intolerance of Uncertainty
A study testing Behavioural Experiments for Intolerance of Uncertainty in people with Generalized Anxiety Disorder and Intolerance of Uncertainty, run by University of Manitoba at 2 sites in Canada.
Trial summary
Generalized anxiety disorder (GAD) is a debilitating condition involving excessive and uncontrollable worry and anxiety. Difficulty tolerating the uncertainties of life, known as intolerance of uncertainty (IU), has been shown to be key in the development and maintenance of GAD symptoms. Read more about this study
- Who is it for?
- Ages 18 to 89 years
- Conditions the study is for
- Generalized Anxiety Disorder, Intolerance of Uncertainty, Anxiety
- What is being tested?
- Behavioural Experiments for Intolerance of Uncertainty
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 2 sitesCanada
- Study dates
- 1 Feb 2021to 30 Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 89 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Primary diagnosis of generalized anxiety disorder (GAD)
- High Intolerance of uncertainty (IU)
Who cannot join
- Comorbid psychosis, organic brain disorder, bipolar disorder, or current substance use disorder
- Receiving concurrent psychological treatments or other counselling
- Psychotropic medications must remain stable during the study period and for 3 months prior to intervention
Trial locations and contacts
2 sites in 1 country.
Canada2 sites
St. Boniface General Hospital
Winnipeg, Manitoba, R2H 2A6
Deer Lodge Centre
Winnipeg, Manitoba, R3J 0L3
About this study
Official title: Facing the Unknown Together: Piloting a Group-based CBT Protocol for Intolerance of Uncertainty
Generalized anxiety disorder (GAD) is a debilitating condition involving excessive and uncontrollable worry and anxiety. Difficulty tolerating the uncertainties of life, known as intolerance of uncertainty (IU), has been shown to be key in the development and maintenance of GAD symptoms. A new, streamlined cognitive-behavioural treatment that targets IU has been shown to be effective in at reducing GAD symptoms, IU, and general psychopathology when delivered one-on-one with a therapist, as shown in a recently published pilot study. The individual format of this treatment is now being evaluated in a randomized controlled trial (RCT). The overall objective of this study is to pilot test a group version of the treatment protocol to determine if a future RCT of this group treatment is both warranted and feasible. We will also conduct a preliminary investigation into the group treatment's efficacy. A total of two pilot groups (N = 12-20) will be conducted with participants recruited from two clinical hospital sites in Winnipeg, Manitoba, Canada. The group treatment protocol will be delivered over the course of 12 weekly therapy sessions. Participants will complete assessment measures at pretreatment, posttreatment, and at a 3-month follow-up point. All assessments and treatment sessions will be conducted virtually via videoconferencing platform due to ongoing COVID-19 pandemic restrictions.
- Being tested
- Behavioural Experiments for Intolerance of Uncertainty
- Medical subject headings
- Generalized Anxiety Disorder, Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Behavioural Experiments for Intolerance of UncertaintyBehavioural
Cognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique
| Study group | Role | What they receive |
|---|---|---|
| IU Group Treatment | Experimental | Clinical intervention arm Receives: Behavioral: Behavioural Experiments for Intolerance of Uncertainty |
What is being measured
The primary outcome is the main question the study is designed to answer.
MINI International Neuropsychiatric Interview
Diagnostic status as measured by the MINI (Sheehan et al., 1994). Clinical Severity Rating adapted from the ADIS, with scores ranging from 0-8 (higher scores indicating greater GAD severity)
Measured: Pretreatment (prior to the intervention).
MINI International Neuropsychiatric Interview
Diagnostic status as measured by the MINI (Sheehan et al., 1994).Clinical Severity Rating adapted from the ADIS, with scores ranging from 0-8 (higher scores indicating greater GAD severity)
Measured: Posttreatment (after completing final session of the treatment intervention)
MINI International Neuropsychiatric Interview
Diagnostic status as measured by the MINI (Sheehan et al., 1994). Clinical Severity Rating adapted from the ADIS, with scores ranging from 0-8 (higher scores indicating greater GAD severity)
Measured: 3-month follow-up
Worry and Anxiety Questionnaire
Self-reported GAD symptoms as measured by the WAQ (Dugas et al., 2001). Scores range from 0-80 with higher scores indicating higher GAD severity.
Measured: Pretreatment (prior to the intervention).
Worry and Anxiety Questionnaire
Self-reported GAD symptoms as measured by the WAQ (Dugas et al., 2001). Scores range from 0-80 with higher scores indicating higher GAD severity.
Measured: Posttreatment (after completing final session of the treatment intervention)
Worry and Anxiety Questionnaire
Self-reported GAD symptoms as measured by the WAQ (Dugas et al., 2001). Scores range from 0-80 with higher scores indicating higher GAD severity.
Measured: 3-month follow-up
Intolerance of Uncertainty Scale
Self-reported difficulties tolerating uncertainty (Freeston, Rhéaume, et al., 1994). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty.
Measured: Pretreatment (prior to the intervention).
Intolerance of Uncertainty Scale
Self-reported difficulties tolerating uncertainty (Freeston, Rhéaume, et al., 1994). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty.
Measured: Posttreatment (after completing final session of the treatment intervention)
Intolerance of Uncertainty Scale
Self-reported difficulties tolerating uncertainty (Freeston, Rhéaume, et al., 1994). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty.
Measured: 3-month follow-up
Secondary outcomes (18)
Depression Anxiety Stress Scales
A measure of self-reported depression, anxiety, and stress symptoms (Lovibond \& Lovibond, 1995). Higher scores on a subscale indicate greater severity in that symptom area (i.e., depression, anxiety, or stress, respectively).
Measured: Pretreatment (prior to the intervention).
Depression Anxiety Stress Scales
A measure of self-reported depression, anxiety, and stress symptoms (Lovibond \& Lovibond, 1995). Higher scores on a subscale indicate greater severity in that symptom area (i.e., depression, anxiety, or stress, respectively).
Measured: Posttreatment (after completing final session of the treatment intervention)
Depression Anxiety Stress Scales
A measure of self-reported depression, anxiety, and stress symptoms (Lovibond \& Lovibond, 1995). Higher scores on a subscale indicate greater severity in that symptom area (i.e., depression, anxiety, or stress, respectively).
Measured: 3-month follow-up
Penn State Worry Questionnaire
A measure of self-reported excessive worry (Meyer, Miller, Metzger, \& Borkovec, 1990). Scores range from 16-80 with higher scores indicating greater worry severity.
Measured: Pretreatment (prior to the intervention).
Penn State Worry Questionnaire
A measure of self-reported excessive worry (Meyer, Miller, Metzger, \& Borkovec, 1990). Scores range from 16-80 with higher scores indicating greater worry severity.
Measured: Posttreatment (after completing final session of the treatment intervention)
Penn State Worry Questionnaire
A measure of self-reported excessive worry (Meyer, Miller, Metzger, \& Borkovec, 1990). Scores range from 16-80 with higher scores indicating greater worry severity.
Measured: 3-month follow-up
Five Dimensional Curiosity Scale
Self-reported tendency toward 5 dimensions of curiosity (Kashdan et al., 2018), with higher scores on each respective subscale indicating greater tendency toward a specific facet of curiousity.
Measured: Pretreatment (prior to the intervention).
Five Dimensional Curiosity Scale
Self-reported tendency toward 5 dimensions of curiosity (Kashdan et al., 2018), with higher scores on each respective subscale indicating greater tendency toward a specific facet of curiousity.
Measured: Posttreatment (after completing final session of the treatment intervention)
Five Dimensional Curiosity Scale
Self-reported tendency toward 5 dimensions of curiosity (Kashdan et al., 2018), with higher scores on each respective subscale indicating greater tendency toward a specific facet of curiousity.
Measured: 3-month follow-up
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form
Self-reported quality of life (Endicott, Nee, Harrison, \& Bulmental, 1993), with scores ranging from 14-70 (higher scores indicating greater overall quality of life).
Measured: Pretreatment (prior to the intervention).
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form
Self-reported quality of life (Endicott, Nee, Harrison, \& Bulmental, 1993), with scores ranging from 14-70 (higher scores indicating greater overall quality of life).
Measured: Posttreatment (after completing final session of the treatment intervention)
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form
Self-reported quality of life (Endicott, Nee, Harrison, \& Bulmental, 1993), with scores ranging from 14-70 (higher scores indicating greater overall quality of life).
Measured: 3-month follow-up
Treatment Acceptability/Adherence Scale
Self-report measure of the participant's perception of the treatment's acceptability and their anticipated adherence to the intervention (Milosevic, Levy, Alcolado, \& Radomsky, 2015). Scores range from 10 to 70 with greater scores indicating greater treatment acceptability and anticipated adherence.
Measured: Midtreatment
GAD Safety Behaviours Questionnaire
Self-reported tendency to use safety behaviours to manage anxiety (Hebert \& Dugas, 2019). Scores range from 18 to 90 with higher scores indicating greater use of safety behaviours.
Measured: Pretreatment (prior to the intervention).
GAD Safety Behaviours Questionnaire
Self-reported tendency to use safety behaviours to manage anxiety (Hebert \& Dugas, 2019). Scores range from 18 to 90 with higher scores indicating greater use of safety behaviours.
Measured: Posttreatment (after completing final session of the treatment intervention)
GAD Safety Behaviours Questionnaire
Self-reported tendency to use safety behaviours to manage anxiety (Hebert \& Dugas, 2019). Scores range from 18 to 90 with higher scores indicating greater use of safety behaviours.
Measured: 3-month follow-up
IUS Past-Week
Self-report measure assessing intolerance of uncertainty in the past week (Dugas, 2008). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty in the past week.
Measured: Weekly from session 1 to session 12 of treatment
Penn State Worry Questionnaire Past-Week
Self-report measure of the tendency to worry excessively in the past week (Stöber, J., \& Bittencourt, J., 1998). Scores range from 0 to 90 with greater scores indicating greater tendency to worry excessively in the past week.
Measured: Weekly from session 1 to session 12 of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Aug 2020
- Study start1 Feb 2021
- Primary completion30 Jun 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Generalized Anxiety DisorderStudies of the same condition, open and under way.
- More trials run by University of ManitobaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Manitoba
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elizabeth Hebert, University of Manitoba
- Investigators
- Elizabeth Hebert, PhD, Principal investigator, University of Manitoba
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04512378
- Sponsor's protocol ID
- H2019:412
- Status last verified
- Jul 2026
- First submitted
- 7 Aug 2020
- Last updated
- 29 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Hebert, E. A., & Dugas, M. J. (2019). Behavioral experiments for intolerance of uncertainty: Challenging the unknown in the treatment of generalized anxiety disorder. Cognitive and Behavioral Practice, 26(2), 421-436. https://doi.org/10.1016/j.cbpra.2018.07.007
Sheehan, D. V., Lecrubier, Y., Janvas, J., Knapp, E., Weiller, E., Sheehan, M., et al. (1994). Mini International Neuropsychiatric Interview Version 4.4 (MINI). Tampa/Paris: University of South Florida/Inserm U302-Hôpital de la Salpêtrière.
Dugas, M. J., Freeston, M. H., Provencher, M. D., Lachance, S., Ladouceur, R., & Gosselin, P. (2001). Journal de Thérapie Comportementale et Cognitive, 11(1), 31-36.
Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-95. doi: 10.1016/0005-7967(90)90135-6.
PubMed 2076086Milosevic I, Levy HC, Alcolado GM, Radomsky AS. The Treatment Acceptability/Adherence Scale: Moving Beyond the Assessment of Treatment Effectiveness. Cogn Behav Ther. 2015;44(6):456-69. doi: 10.1080/16506073.2015.1053407. Epub 2015 Jun 19.
PubMed 26091250Freeston, M. H., Rhéaume, J., Letarte, H., Dugas, M. J., & Ladouceur, R. (1994). Why do people worry? Personality and Individual Differences, 17, 791-802. https://doi.org/10.1016/0191-8869(94)90048-5
Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995 Mar;33(3):335-43. doi: 10.1016/0005-7967(94)00075-u.
PubMed 7726811Kashdan, T.B., Stiksma, M.C., Disabato, D., McKnight, P.E., Bekier, J., Kaji, J., & Lazarus, R. (in press). The five-dimensional curiosity scale: Capturing the bandwidth of curiosity and identifying four unique subgroups of curious people. Journal of Research in Personality
Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-6.
PubMed 8290681Stober J, Bittencourt J. Weekly assessment of worry: an adaptation of the Penn State Worry Questionnaire for monitoring changes during treatment. Behav Res Ther. 1998 Jun;36(6):645-56. doi: 10.1016/s0005-7967(98)00031-x.
PubMed 9648338Dugas, M.J. (2008). Échelle d'intolérance à l'incertitude - Dernière semaine. Montréal, Canada: Clinique des troubles anxieux, Hôpital du Sacré-Coeur de Montréal.
Study at a glance
From the registry record, last updated by the sponsor on 29 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Facing the Unknown Together: Piloting a Group-based CBT Protocol for Intolerance of Uncertainty
- ClinicalTrials.gov ID
- NCT04512378
- Acronym / sponsor ID
- H2019:412
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 6 participants (actual)
- Lead sponsor
- University of ManitobaUniversity, hospital or other
- Study start
- 1 Feb 2021 (actual)
- Primary completion
- 30 Jun 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 13 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Generalized anxiety disorder (GAD) is a debilitating condition involving excessive and uncontrollable worry and anxiety. Difficulty tolerating the uncertainties of life, known as intolerance of uncertainty (IU), has been shown to be key in the development and maintenance of GAD symptoms. A new, streamlined cognitive-behavioural treatment that targets IU has been shown to be effective in at reducing GAD symptoms, IU, and general psychopathology when delivered one-on-one with a therapist, as shown in a recently published pilot study. The individual format of this treatment is now being evaluated in a randomized controlled trial (RCT). The overall objective of this study is to pilot test a group version of the treatment protocol to determine if a future RCT of this group treatment is both warranted and feasible. We will also conduct a preliminary investigation into the group treatment's efficacy. A total of two pilot groups (N = 12-20) will be conducted with participants recruited from two clinical hospital sites in Winnipeg, Manitoba, Canada. The group treatment protocol will be delivered over the course of 12 weekly therapy sessions. Participants will complete assessment measures at pretreatment, posttreatment, and at a 3-month follow-up point. All assessments and treatment sessions will be conducted virtually via videoconferencing platform due to ongoing COVID-19 pandemic restrictions.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| IU Group Treatment | Experimental | Behavioral: Behavioural Experiments for Intolerance of UncertaintyClinical intervention arm |
Who may qualify
- Ages
- 18 to 89 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Primary diagnosis of generalized anxiety disorder (GAD)
- High Intolerance of uncertainty (IU)
Key exclusion criteria (3 listed)
- Comorbid psychosis, organic brain disorder, bipolar disorder, or current substance use disorder
- Receiving concurrent psychological treatments or other counselling
- Psychotropic medications must remain stable during the study period and for 3 months prior to intervention
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Behavioural Experiments for Intolerance of UncertaintyCognitive-behavioural treatment targeting intolerance of uncertainty using behavioural experiment technique | Behavioural | IU Group Treatment |
Primary outcome
MINI International Neuropsychiatric Interview
Time frame: Pretreatment (prior to the intervention).
Diagnostic status as measured by the MINI (Sheehan et al., 1994). Clinical Severity Rating adapted from the ADIS, with scores ranging from 0-8 (higher scores indicating greater GAD severity)
MINI International Neuropsychiatric Interview
Time frame: Posttreatment (after completing final session of the treatment intervention)
Diagnostic status as measured by the MINI (Sheehan et al., 1994).Clinical Severity Rating adapted from the ADIS, with scores ranging from 0-8 (higher scores indicating greater GAD severity)
MINI International Neuropsychiatric Interview
Time frame: 3-month follow-up
Diagnostic status as measured by the MINI (Sheehan et al., 1994). Clinical Severity Rating adapted from the ADIS, with scores ranging from 0-8 (higher scores indicating greater GAD severity)
Worry and Anxiety Questionnaire
Time frame: Pretreatment (prior to the intervention).
Self-reported GAD symptoms as measured by the WAQ (Dugas et al., 2001). Scores range from 0-80 with higher scores indicating higher GAD severity.
Worry and Anxiety Questionnaire
Time frame: Posttreatment (after completing final session of the treatment intervention)
Self-reported GAD symptoms as measured by the WAQ (Dugas et al., 2001). Scores range from 0-80 with higher scores indicating higher GAD severity.
Worry and Anxiety Questionnaire
Time frame: 3-month follow-up
Self-reported GAD symptoms as measured by the WAQ (Dugas et al., 2001). Scores range from 0-80 with higher scores indicating higher GAD severity.
Intolerance of Uncertainty Scale
Time frame: Pretreatment (prior to the intervention).
Self-reported difficulties tolerating uncertainty (Freeston, Rhéaume, et al., 1994). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty.
Intolerance of Uncertainty Scale
Time frame: Posttreatment (after completing final session of the treatment intervention)
Self-reported difficulties tolerating uncertainty (Freeston, Rhéaume, et al., 1994). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty.
Intolerance of Uncertainty Scale
Time frame: 3-month follow-up
Self-reported difficulties tolerating uncertainty (Freeston, Rhéaume, et al., 1994). Scores range from 27-135 with greater scores indicating greater intolerance of uncertainty.
18 secondary outcomes
Depression Anxiety Stress Scales
Time frame: Pretreatment (prior to the intervention).
Depression Anxiety Stress Scales
Time frame: Posttreatment (after completing final session of the treatment intervention)
Depression Anxiety Stress Scales
Time frame: 3-month follow-up
Penn State Worry Questionnaire
Time frame: Pretreatment (prior to the intervention).
Penn State Worry Questionnaire
Time frame: Posttreatment (after completing final session of the treatment intervention)
Penn State Worry Questionnaire
Time frame: 3-month follow-up
Five Dimensional Curiosity Scale
Time frame: Pretreatment (prior to the intervention).
Five Dimensional Curiosity Scale
Time frame: Posttreatment (after completing final session of the treatment intervention)
Five Dimensional Curiosity Scale
Time frame: 3-month follow-up
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form
Time frame: Pretreatment (prior to the intervention).
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form
Time frame: Posttreatment (after completing final session of the treatment intervention)
Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form
Time frame: 3-month follow-up
Treatment Acceptability/Adherence Scale
Time frame: Midtreatment
GAD Safety Behaviours Questionnaire
Time frame: Pretreatment (prior to the intervention).
GAD Safety Behaviours Questionnaire
Time frame: Posttreatment (after completing final session of the treatment intervention)
GAD Safety Behaviours Questionnaire
Time frame: 3-month follow-up
IUS Past-Week
Time frame: Weekly from session 1 to session 12 of treatment
Penn State Worry Questionnaire Past-Week
Time frame: Weekly from session 1 to session 12 of treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jul 2026.
- BackgroundHebert, E. A., & Dugas, M. J. (2019). Behavioral experiments for intolerance of uncertainty: Challenging the unknown in the treatment of generalized anxiety disorder. Cognitive and Behavioral Practice, 26(2), 421-436. https://doi.org/10.1016/j.cbpra.2018.07.007
- BackgroundSheehan, D. V., Lecrubier, Y., Janvas, J., Knapp, E., Weiller, E., Sheehan, M., et al. (1994). Mini International Neuropsychiatric Interview Version 4.4 (MINI). Tampa/Paris: University of South Florida/Inserm U302-Hôpital de la Salpêtrière.
- BackgroundDugas, M. J., Freeston, M. H., Provencher, M. D., Lachance, S., Ladouceur, R., & Gosselin, P. (2001). Journal de Thérapie Comportementale et Cognitive, 11(1), 31-36.
- Background: PubMed 2076086Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-95. doi: 10.1016/0005-7967(90)90135-6.
- Background: PubMed 26091250Milosevic I, Levy HC, Alcolado GM, Radomsky AS. The Treatment Acceptability/Adherence Scale: Moving Beyond the Assessment of Treatment Effectiveness. Cogn Behav Ther. 2015;44(6):456-69. doi: 10.1080/16506073.2015.1053407. Epub 2015 Jun 19.
- BackgroundFreeston, M. H., Rhéaume, J., Letarte, H., Dugas, M. J., & Ladouceur, R. (1994). Why do people worry? Personality and Individual Differences, 17, 791-802. https://doi.org/10.1016/0191-8869(94)90048-5
- Background: PubMed 7726811Lovibond PF, Lovibond SH. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995 Mar;33(3):335-43. doi: 10.1016/0005-7967(94)00075-u.
- BackgroundKashdan, T.B., Stiksma, M.C., Disabato, D., McKnight, P.E., Bekier, J., Kaji, J., & Lazarus, R. (in press). The five-dimensional curiosity scale: Capturing the bandwidth of curiosity and identifying four unique subgroups of curious people. Journal of Research in Personality
- Background: PubMed 8290681Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321-6.
- Background: PubMed 9648338Stober J, Bittencourt J. Weekly assessment of worry: an adaptation of the Penn State Worry Questionnaire for monitoring changes during treatment. Behav Res Ther. 1998 Jun;36(6):645-56. doi: 10.1016/s0005-7967(98)00031-x.
- BackgroundDugas, M.J. (2008). Échelle d'intolérance à l'incertitude - Dernière semaine. Montréal, Canada: Clinique des troubles anxieux, Hôpital du Sacré-Coeur de Montréal.
- Individual participant dataSharing planned: No
Related trials for Generalized Anxiety Disorder
RecruitingObservational study
Preoperative Anxiety and One-year Patient-reported Outcomes in Orthopedic Surgery Patients Receiving Enhanced Recovery After Surgery or Conventional Care
Preoperative Anxiety, Orthopedic Surgery
Not yet recruiting
Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder
Generalized Anxiety Disorder (GAD)
Not yet recruiting
Effectiveness of Internet-based Unified Protocol (iUP) for Emotional Problems: A Randomized Controlled Trial
Depression - Major Depressive Disorder, Generalised Anxiety Disorder
Active, not recruiting
Future School of Comprehensive Well-Being
Learning, Comprehensive Wellbeing
Active, not recruiting
Targeting Social Function in Anxiety and Eating Disorders
Eating Disorders, Anorexia Nervosa
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elizabeth Hebert, PhD principal investigator
University of Manitoba
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Behavioural Experiments for Intolerance of Uncertainty in people with Generalized Anxiety Disorder and Intolerance of Uncertainty, run by University of Manitoba at 2 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MINI International Neuropsychiatric Interview (time frame: Pretreatment (prior to the intervention).). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04512378, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jul 2026.